SP1-SuperEnhancer-SPHK1轴在TNBC中调解了尼拉帕里布抗性
Yu-Xia Yuan1,2, Rui-Jia Chen1,2, Gui-Hui Tu1,2
1Department of Pharmacology, School of Pharmacy, Fujian Medical University, Fuzhou 350000, China.
三重阴性乳腺癌中尼拉巴里布耐药性是由SP1-超级增强剂-SPHK1通路驱动的. 天然化合物Echinatin通过抑制SP1来逆转这种抵抗,增强Niraparib.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- PARP抑制剂对BRCA突变癌症有效,但由于罕见的突变和耐药性而面临限制.
- 三重阴性乳腺癌 (TNBC) 对PARP抑制剂治疗提出了独特的挑战.
- 了解耐药机制对于提高治疗疗效至关重要.
研究的目的:
- 调查Niraparib对TNBC中脂代谢和SPHK1的影响.
- 阐明一种新型超级增强剂 (SE) 介导的尼拉巴里布耐药性机制.
- 使用人工智能进行化合物选,以克服Niraparib耐药性.
主要方法:
- 多omics分析以确定分子通路.
- 研究了转录因子SP1和超级增强剂的作用.
- 基于人工智能的虚拟查用于药物发现.
- 在体外测试以验证发现和协同效应.
主要成果:
- 尼拉帕里布通过SP1-SE轴上调节SPHK1,从而导致TNBC的抵抗.
- 由Niraparib抑制SP1增强了它与SE的结合,促进了SPHK1的表达.
- 人工智能查发现,乙素是一种强大的SP1抑制剂,与Niraparib具有协同作用.
- 与直接针对SPHK1相比,乙素显示出更好的毒性概况.
结论:
- 尼拉帕里布耐药性是由SP1-SE-SPHK1信号轴介导的.
- 乙素通过抑制SP1.1,有效地逆转Niraparib耐药性.
- 这项研究提出了Niraparib和Echinatin用于TNBC的新型组合疗法.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
相关概念视频
Abnormal Proliferation
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Treatment Resistant Cancers
The Intrinsic Apoptotic Pathway
Targeted Cancer Therapies
There are several types of targeted therapies against...
